Drug Profile
CA 170
Alternative Names: CA-170Latest Information Update: 04 Jan 2023
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology; Curis
- Class Antineoplastics; Small molecules
- Mechanism of Action Programmed cell death 1 ligand 2 inhibitors; Programmed cell death-1 ligand-1 inhibitors; VISTA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bladder cancer; Non-small cell lung cancer; Renal cancer
- Phase II Lymphoma; Solid tumours
- No development reported Mesothelioma
Most Recent Events
- 04 Jan 2023 Phase-III clinical trials in Bladder cancer in Asia (PO), prior to January 2023 (Aurigene Discovery Technologies pipeline, January 2023)
- 04 Jan 2023 Phase-III clinical trials in Non-small cell lung cancer in Asia (PO), prior to January 2023 (Aurigene Discovery Technologies pipeline, January 2023)
- 04 Jan 2023 Phase-III clinical trials in Renal cancer in Asia (PO), prior to January 2023 (Aurigene Discovery Technologies pipeline, January 2023)